| Bid | 5.14 |
| Market Cap | 229.75M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -3.14 |
| PE Ratio (ttm) | -1.64 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 5.16 |
| Volume | 258,227 |
| Avg. Volume (20D) | 1,586,140 |
| Open | 5.23 |
| Previous Close | 5.04 |
| Day's Range | 5.15 - 5.47 |
| 52-Week Range | 2.10 - 14.22 |
| Beta | undefined |
About VSTM
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel coho...
Analyst Forecast
According to 8 analyst ratings, the average rating for VSTM stock is "Buy." The 12-month stock price forecast is $13, which is an increase of 151.83% from the latest price.
Next Earnings Release
Analysts project revenue of $100.00K, reflecting a n/a YoY growth and earnings per share of -0.68, making a -38.18% decrease YoY.
2 months ago · businesswire.com
Verastem Oncology to Participate in Upcoming Investor ConferencesBOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will part...
